(22 days)
Not Found
No
The document describes a human plasma control product for quality control in D-dimer assays and does not mention any AI or ML components.
No.
The device is a human plasma control used for quality control in D-dimer assays, not for treating a disease or condition.
No
Explanation: This device is a control material used for quality control in D-dimer assays, not a device that directly diagnoses a patient's condition. It helps ensure the accuracy of diagnostic tests.
No
The device is a lyophilized human plasma based product, which is a physical substance, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is a "human plasma control that is suitable for use as an abnormal control with patient citrated plasma in D-dimer assays." D-dimer assays are performed in vitro (outside the body) on patient samples to aid in diagnosis or monitoring.
- Device Description: It is a "lyophilized human plasma based product" used in a laboratory setting.
- Intended User / Care Setting: It is intended for use in a "Coagulation laboratory," which is a typical setting for in vitro diagnostic testing.
- Predicate Device: The predicate device is also a "D-Dimer Control," further indicating its use in in vitro diagnostic procedures.
All these points align with the definition of an In Vitro Diagnostic device, which is used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes.
N/A
Intended Use / Indications for Use
Sigma Diagnostics ACCUMARK AUTO D-Dimer Control, Level 3 is a human plasma control that is suitable for use as an abnormal control with patient citrated plasma in the Sigma Diagnostics AUTO D-Dimer assays. Plasma controls are routinely used in the coagulation laboratory as a means of quality control.
Product codes (comma separated list FDA assigned to the subject device)
DAP
Device Description
Sigma Diagnostics AUTO D-Dimer Control, Level 3 is a lyophilized human plasma based product. After reconstitution with water, AUTO D-Dimer Control, Level 3 is stable for 3 days when stored at 2-8°C and 24 hours when stored at 18-26°C.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The safety and effectiveness of the Sigma Diagnostics AUTO D-Dimer Control, Level 3 (Cat. No. A8221) has been demonstrated by its substantial equivalence to the Sigma Diagnostics AUTO D-Dimer Control, Level 2 (Cat. No. A5217, K003329).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 864.7320 Fibrinogen/fibrin degradation products assay.
(a)
Identification. A fibrinogen/fibrin degradation products assay is a device used to detect and measure fibrinogen degradation products and fibrin degradation products (protein fragments produced by the enzymatic action of plasmin on fibrinogen and fibrin) as an aid in detecting the presence and degree of intravascular coagulation and fibrinolysis (the dissolution of the fibrin in a blood clot) and in monitoring therapy for disseminated intravascular coagulation (nonlocalized clotting in the blood vessels).(b)
Classification. Class II (performance standards).
0
NOV 1 5 2001
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS AUTO D-Dimer Control, Level 3, Cat. No. A8221
Image /page/0/Picture/2 description: The image shows text describing Sigma Diagnostics ACCUMARKTM AUTO D-Dimer Control, Level 3. It is a human plasma control suitable for use as an elevated control with patient citrated plasma in the Sigma Diagnostics AUTO D-dimer assay. The text provides information about the product and its intended use. It is a control used in the Sigma Diagnostics AUTO D-dimer assay.
The safety and effectiveness of the Sigma Diagnostics AUTO D-Dimer Control, Level 3 (Cat. No. A8221) has been demonstrated by its substantial equivalence to the Sigma Diagnostics AUTO D-Dimer Control, Level 2 (Cat. No. A5217, K003329).
Sigma Diagnostics AUTO D-Dimer Control, Level 3 is a lyophilized human plasma based product. After reconstitution with water, AUTO D-Dimer Control, Level 3 is stable for 3 days when stored at 2-8°C and 24 hours when stored at 18-26°C.
ર્વ ર
1
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/1/Picture/1 description: The image shows the seal of the Department of Health & Human Services - USA. The seal features an eagle-like symbol with three stylized profiles facing right, representing people. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the symbol.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
William R. Gilbert, Ph.D. Manager, Scientific Affairs Sigma Diagnostics, Inc. 545 South Ewing Avenue St. Louis, Missouri 63103
NOV 1 5 2001
K013545 Re:
Trade Name: Sigma Diagnostics ACCUMARK™ AUTO D-Dimer Control, Level 3 Regulation Number: 21 CFR § 864.7320 Regulation Name: Fibrinogen/Fibrin Degradation Products Assay Regulatory Class: II Product Code: DAP Dated: October 19, 2001 Received: October 24, 2001
Dear Dr. Gilbert:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
2
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
NOV 1 5 200.
Device Name: _Sigma Diagnostics ACCUMARK™ AUTO D-Dimer Control, Level 3
Indications For Use: NOV 1 5 2001
Sigma Diagnostics ACCUMARK™ AUTO D-Dimer Control, Level 3 is a human plasma Olgina Diagnootion AS & Come as an abnormal control with patient citrated plasma in Dcontrol that is outlable for assays. Plasma controls are routinely used in the coagulation laboratory as a means of quality control.
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Josephine Bautista
Devices sion of Clinical La 510(k) Number -
Image /page/3/Picture/10 description: The image shows the words "Prescription Use" in bold font, followed by a check mark. Below that, the text "(Per 21 CFR 801.109)" is printed in a smaller, regular font. The text indicates that the product is for prescription use only, as defined by the Code of Federal Regulations.
OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________